Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2013-08-29
Last Posted Date
2015-12-31
Lead Sponsor
Yale University
Target Recruit Count
12
Registration Number
NCT01931865
Locations
🇺🇸

Yale Physician Building, New Haven, Connecticut, United States

OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2013-08-12
Last Posted Date
2016-10-26
Lead Sponsor
St. Luke's-Roosevelt Hospital Center
Target Recruit Count
6
Registration Number
NCT01920945
Locations
🇺🇸

Roosevelt Hospital Headache Institute, New York, New York, United States

A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation

First Posted Date
2013-08-06
Last Posted Date
2018-10-18
Lead Sponsor
Allergan
Target Recruit Count
59
Registration Number
NCT01917006
Locations
🇺🇸

Manhattan Medical Research, New York, New York, United States

🇬🇧

King's College Hospital, London, United Kingdom

🇬🇧

Celerion, Belfast, United Kingdom

and more 7 locations

Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS

First Posted Date
2013-07-30
Last Posted Date
2015-10-02
Lead Sponsor
University of Manitoba
Target Recruit Count
12
Registration Number
NCT01911377
Locations
🇨🇦

WRHA Health Sciences Centre Rehabilitation Hospital, Winnipeg, Manitoba, Canada

Early Use of Botulinum Toxin in Spasticity Post Stroke.

First Posted Date
2013-06-20
Last Posted Date
2014-11-18
Lead Sponsor
Sandwell & West Birmingham Hospitals NHS Trust
Target Recruit Count
120
Registration Number
NCT01882556
Locations
🇬🇧

Sandwell and West Birmingham NHS Trust, Birmingham, West Midlands, United Kingdom

Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength During Locomotion in Chronic Hemiparetic Patients

First Posted Date
2013-04-01
Last Posted Date
2019-05-30
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
36
Registration Number
NCT01821573
Locations
🇫🇷

Service de médecine physique et réadaptation CHU de Brest, Brest, Bretagne, France

🇫🇷

Centre de rééducation de l'ADAPT Montargis, Amilly, Loiret, France

🇫🇷

Nicolas Roche, Garches, Hauts-de-Seine, France

Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2013-03-26
Last Posted Date
2014-05-07
Lead Sponsor
Revance Therapeutics, Inc.
Target Recruit Count
311
Registration Number
NCT01818076
Locations
🇺🇸

Nashville Centre for Laser and Facial Surgery, Nashville, Tennessee, United States

Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-01-28
Last Posted Date
2014-05-07
Lead Sponsor
Revance Therapeutics, Inc.
Target Recruit Count
247
Registration Number
NCT01776606
Locations
🇺🇸

Dermatology Research Institute, Coral Gables, Florida, United States

Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding

First Posted Date
2012-11-27
Last Posted Date
2017-03-08
Lead Sponsor
Buddhist Tzu Chi General Hospital
Target Recruit Count
70
Registration Number
NCT01733290
Locations
🇨🇳

Buddhist Tzu Chi General Hospital, Hualien, Taiwan

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

First Posted Date
2012-10-04
Last Posted Date
2020-08-18
Lead Sponsor
Cady, Roger, M.D.
Target Recruit Count
20
Registration Number
NCT01700387
Locations
🇺🇸

Clinvest/A Division of Banyan Group, Inc., Springfield, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath